BIOAGE Labs Inc (BIOA) Stock Analysis
Verdict: WATCH (do not buy)
A $188.9M cash buffer funds Phase 1 metabolic pipeline trials, but $82.4M annual burn and clinical trial execution risks demand caution.
Investment score: 46/100
Analysis as of
Is BIOAGE Labs Inc stock worth reviewing? The TradeMates thesis
The model views BioAge Labs as a high-risk clinical biotech with a strong $188.89M cash runway (~27.5 months) offset by steep technical downside momentum and early-stage pipeline risks.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
BIOAGE Labs Inc opportunities and risks
What speaks for BIOA
- Substantial cash runway of 27.5 months ($188.89M cash balance as of Dec 2025 vs -$82.35M 2025 FCF burn)
What speaks against BIOA
- Elevated annual burn rate of -$82.35M FCF against near-zero revenue ($8.995M in 2025)
Peers and competitors
- RLMD
- NIKA
- AVIR
- TTRX
- PLTH.CN
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BIOA | n/a | 28.6x | n/a | 99.4% | -912.3% | -29.8% |
| RLMD | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.2% |
| NIKA | n/a | 0.0x | n/a | 0.0% | 0.0% | -0.0% |
| AVIR | n/a | 0.0x | n/a | 0.0% | 0.0% | -36.1% |
| TTRX | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.0% |
| PLTH.CN | n/a | 0.5x | n/a | 41.0% | -66.9% | -22.5% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.2% |
Frequently asked questions about BIOAGE Labs Inc (BIOA)
Is BIOA stock a good investment?
The TradeMates model rates BIOAGE Labs Inc as WATCH (do not buy) with an investment score of 46/100. The model views BioAge Labs as a high-risk clinical biotech with a strong $188.89M cash runway (~27.5 months) offset by steep technical downside momentum and early-stage pipeline risks. This is algorithmic model output, not personal investment advice.
Is BIOA stock a buy?
The TradeMates model verdict for BIOA is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.